Background: Since the early 90s, a growing body of evidence has indicated that the mild to moderate consumption of wine, has a protective effect against cardiovascular diseases.
Methods: The IVV study is a first long-term, prospective, multicenter, randomized trial comparing the effects of red (RW) and white wine (WW) on atherosclerosis markers. 146 healthy subjects at mild to moderate risk of atherosclerosis have been randomized to a regular consumption of red wine (Pinot Noir) or white wine (Chardonnay-Pinot) /1 producer, 1 terroir/ for one year (women 0,2 l, men 0,3 l, 5 times a week, logbook for wine and other alcoholic beverages consumption). The primary endpoint is the level of HDL-cholesterol at one year, secondary endpoints are the levels of other markers of atherosclerosis (LDL-cholesterol, C-reactive protein) and oxidative stress (Lp-PLA2, Copeptin).
Results: The level of HDL significantly decreased at 6 months in WW group in comparison with baseline value (Table 1). We did not detect any differences in the levels of ALT, GGT or bilirubin.
Conclusion: In this prospective randomized trial we did not find between long-term mild consumption of red or white wine any clinically relevant differences in the lipid profile, CRP, fasting blood glucose, other markers of atherosclerosis i.e. Lp-PLA2 or copeptin, and liver function tests. Moreover, we were unable to confirm the hypothesis coming mostly from the retrospective studies that wine drinking is associated with elevation of HDL.
The study is registred by ISRCTN under Ref. No. 54359610.